Search Medical Condition
Please enter condition
Please choose location from dropdown

Carbon-Blanc, France Clinical Trials

A listing of Carbon-Blanc, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (461) clinical trials

French Lumbar Total Disk Replacement Observational Study

Secondary objectives: The secondary objectives are: Describe the reasons for re-interventions operated floor and / or (x) level (s) adjacent (s) Describe the evolution of the function with the functional Oswestry score Describe the evolution of lumbar radicular pain by visual analog scale (VAS) Describe the evolution of the quality ...

Phase N/A

1.47 miles

Learn More »

Cerebellar Stroke and Mood Disorders

Stroke is the leading cause of acquired disability in adults. Beyond these physical consequences, stroke is a major cause of mood disorders (depression, anxiety, apathy), affecting more than 30% of patients at 3 months after the initial accident. These mood disorders impair patient's quality of life and their post-stroke functional ...

Phase N/A

1.86 miles

Learn More »

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Standard of treatments: In Europe, advanced ovarian cancer patients are treated in first line with optimal debulking surgery followed by carboplatin/paclitaxel regimen plus bevacizumab during chemotherapy and as maintenance for a total 15 months. The addition of bevacizumab is a standard for the patients with residual disease. The addition of ...

Phase

2.87 miles

Learn More »

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

After surgery, most of patients with advanced ovarian/primitive peritoneal /fallopian carcinoma received as first line treatment, carboplatin plus paclitaxel plus or minus bevacizumab for 6 cycles followed by surveillance or bevacizumab maintenance therapy up to one year (GOG (Burger et al.), ICON7 (Perren et al.), French national guidelines Saint Paul ...

Phase

2.87 miles

Learn More »

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Patient will receive either one infusion of rituximab IV and seven administrations of rituximab SC (experimental arm) or four infusions of rituximab IV (standard arm). The hypothesis is that the use of rituximab by sub cutaneous route and the scheme of administration could: optimize rituximab exposure leading to improve response ...

Phase

2.87 miles

Learn More »

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance improves progression free survival (PFS) compared to standard rituximab maintenance after induction treatment consisting of R-CHOP + R-HAD versus R-CHOP alone in older patients ( 60 year old) with mantle cell lymphoma. 643 patients will be randomized in ...

Phase

2.87 miles

Learn More »

Phase II Study to Evaluate the Combination of Rituximab and DepoCyte in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis

The purpose of this study is to measure the rate of complete response (CR and UCR) at the end of a course of immuno-chemotherapy: - before cerebral radiotherapy for PCL - after the course of immuno-chemotherapy for aggressive lymphomas with neuromeningeal involvement Toxicity of the protocol Overall survival Survival without ...

Phase

2.87 miles

Learn More »

Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

OBJECTIVES: Primary - Evaluate the objective response (RECIST criteria) at 6 months associated with FOLFIRI and bevacizumab therapy. - Evaluate the tolerability (NCI CTC v. 2.0 criteria) of this treatment. Secondary - Evaluate progression-free survival and overall survival. - Determine the time to treatment failure. - Evaluate the quality of ...

Phase

2.87 miles

Learn More »

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Due to anti-arrhythmic pharmacological drugs failure to suppress atrial fibrillation (AF), interest towards preventive pacing treatments is increasing. The importance of this option in the panoply of the preventive tools is fully justified, only by considering the insufficiency, the complexity, or the poor reproducibility of the other non-pharmaceutical approaches. Preventive ...

Phase

2.87 miles

Learn More »

International Breast Cancer Biomarker Standard of Care and Real World Outcomes Study

Background/Rationale: Within the setting of metastatic human epidermal growth factor receptor 2 negative (HER2-ve) breast cancer limited epidemiological data exist on the prevalence of pathogenic mutations of breast cancer susceptibility gene (BRCA) and other homologous recombination repair (HRR) genes. There are also limited data on the treatments and clinical outcomes ...

Phase N/A

2.87 miles

Learn More »